Scarica l'app Stockscreener
6.50
1.40%
0.09
Pre-mercato:
6.90
0.40
+6.15%
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlitetm in Landmark CREDENCE Trial - Lelezard
[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity - Stock Titan
Director at Precision Bio (NASDAQ: DTIL) receives 20,979 restricted stock units - Stock Titan
Precision Biosciences (DTIL) director receives grant of 20,979 restricted stock units - Stock Titan
Precision BioSciences (DTIL) director receives grant of 20,979 RSUs - Stock Titan
Precision BioSciences stock (US74019P1084): shares edge higher amid biotech volatility - AD HOC NEWS
Executive at Precision BioSciences (DTIL) receives 57,389 RSU compensation award - Stock Titan
Precision BioSciences (DTIL) awards 107,604 RSUs to General Counsel - Stock Titan
Precision BioSciences (NASDAQ: DTIL) CEO receives 573,888 restricted stock units - Stock Titan
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Guggenheim Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $19 - Moomoo
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences Shareholders Approve Incentive Plan and Directors - The Globe and Mail
DTIL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Precision BioSciences (DTIL) Unveils Groundbreaking Data on PBGE - GuruFocus
Precision BioSciences Put Its ARCUS Gene Editing Data Front And Center - Finimize
Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial ResultsSlideshow (NASDAQ:DTIL) 2026-05-27 - Seeking Alpha
Precision BioSciences stock jumps on hepatitis B trial data By Investing.com - Investing.com South Africa
Precision BioSciences stock jumps on hepatitis B trial data - Investing.com
Precision BioSciences Reports Promising New Hepatitis B Trial Data - TipRanks
Why Is Precision BioSciences Stock Gaining Wednesday?Precision BioSciences (NASDAQ:DTIL) - Benzinga
Precision BioSciences Approves Amendments to 2019 Incentive Award Plan and Certificate of Incorporation - Minichart
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - BioSpace
New PBGENE-HBV hepatitis B data from Precision BioSciences (Nasdaq: DTIL) - Stock Titan
Experimental gene edit targets hepatitis B DNA in early patient biopsies - Stock Titan
Precision BioSciences (DTIL) shareholders approve 3.8M-share incentive plan increase and officer exculpation - Stock Titan
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Precision Biosciences (DTIL) director gains 21,000 shares as RSUs vest into common stock - Stock Titan
Director at Precision BioSciences (DTIL) sees 21,000 RSUs vest into common stock - Stock Titan
Director Melinda Brown receives 21,000 DTIL shares as RSUs vest (DTIL) - Stock Titan
Precision BioSciences (DTIL) director gains 21,000 shares from RSU vesting - Stock Titan
Precision Biosciences (NASDAQ: DTIL) director’s 21,000 RSUs vest into shares - Stock Titan
DTIL: Shareholders approved all proposals as the company advanced key clinical programs and strengthened its finances - TradingView
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINA - pharmiweb.com
Precision BioSciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 - marketscreener.com
Precision BioSciences stock (US74019P1084): earnings miss and volatile recovery in gene editing play - AD HOC NEWS
Precision BioSciences stock (US74019P1084): gene-editing player in focus after fresh ECUR?506 trial - AD HOC NEWS
Newborn gene trial cuts life-threatening ammonia crises by up to 65% - Stock Titan
Precision BioSciences stock (US74019P1084): gene-editing player updates clinical pipeline and strate - AD HOC NEWS
Number of shareholders of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences (DTIL) Highlights Promising Data in DMD Tr - GuruFocus
Precision Biosciences Presents New Preclinical Data Supporting Advancement of Pbgene-Dmd into Clinic - marketscreener.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Cl - PharmiWeb.com
Precision BioSciences (DTIL) Highlights Promising Data in DMD Treatment - GuruFocus
Precision BioSciences presents DMD gene therapy preclinical data By Investing.com - Investing.com Australia
Precision BioSciences presents DMD gene therapy preclinical data - Investing.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - Business Wire
Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher - simplywall.st
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts - Yahoo Finance
1.13%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):